Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8486001 | Vaccine | 2018 | 8 Pages |
Abstract
Light to moderate alcohol use does not negatively impact adherence or retention in phase I clinical trials. Based on these screening data and the low infection rate of participants during the trial period, the screening process for participation in HVTN phase 1 trials has largely been successful in enrolling and retaining individuals with lower risk profiles. Focusing on binge drinking and increased HIV/STI risk during risk reduction counseling may be warranted.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Arame Thiam-Diouf, Barbara Metch, Cameron Sharpe, Robel Mulugeta, Michele Peake Andrasik,